Medpace Holdings (MEDP) is trading higher by about 3.15% on Friday, April 24, 2026, as dip buyers step in following a steep decline that followed the company’s Q1 2026 update. The rebound appears driven by investors rebalancing after the initial reaction focused less on the quarter’s reported earnings and more on forward-looking demand signals such as bookings and cancellations.

In its Q1 2026 materials dated April 22, 2026, Medpace reported revenue of $706.6 million (up 26.5% year over year) and diluted EPS of $4.28, with net income of $123.9 million. The company also posted non-GAAP EBITDA of $149.4 million and highlighted strong cash generation, including free cash flow of $145.0 million in the quarter. (investor.medpace.com)

Medpace’s full-year 2026 outlook remained intact, with revenue guided to $2.755 billion to $2.855 billion and diluted EPS guided to $16.68 to $17.50 (as of April 22, 2026). While the quarter’s EPS performance supported the bull case, the prior-day drawdown reflected investor concern that bookings-related metrics could imply deceleration risk even with solid near-term results—setting up today’s bounce as positioning normalizes. (investor.medpace.com)

Near-term trading is likely to be driven by any incremental commentary on bookings, cancellations, and book-to-bill trends, since those data points can reset expectations for Medpace’s growth trajectory. Investors will also focus on whether the company can sustain margins and cash conversion while maintaining the current 2026 guidance ranges. (investor.medpace.com)